---
title: "GE HealthCare, Mayo Clinic launch MI-BET study to personalize radioligand therapy in advanced prostate cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292072313.md"
description: "GE HealthCare and Mayo Clinic have launched the MI-BET study to personalize radioligand therapy for advanced prostate cancer. The research focuses on adaptive treatment strategies, such as pausing therapy based on individual response rather than fixed cycles. Utilizing StarGuide SPECT/CT and MIM LesionID Pro, the program aims to develop predictive markers for earlier decision-making. The study is based at Mayo Clinic’s Rochester campus."
datetime: "2026-07-08T13:01:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292072313.md)
  - [en](https://longbridge.com/en/news/292072313.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292072313.md)
generator: "portal-rs"
---

# GE HealthCare, Mayo Clinic launch MI-BET study to personalize radioligand therapy in advanced prostate cancer

-   GE HealthCare launched MI-BET, a Mayo Clinic research collaboration to test imaging- and biomarker-guided personalization of radioligand therapy in advanced prostate cancer. \* Study targets adaptive treatment, including pausing therapy based on individual disease response instead of fixed treatment cycles. \* Program uses StarGuide SPECT/CT with MIM LesionID Pro to track tumor response, aiming to develop predictive markers for earlier treatment decisions. \* Work will be based at Mayo Clinic’s Rochester campus; Mayo will be the first US site to investigate StarGuide GX, which is not FDA-cleared. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260708929448) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [GEHC.US](https://longbridge.com/en/quote/GEHC.US.md)

## Related News & Research

- [BTIG Research Reiterates "Buy" Rating for GE HealthCare Technologies (NASDAQ:GEHC)](https://longbridge.com/en/news/296356783.md)
- [GE HealthCare Technologies Inc. $GEHC Stock Position Increased by Barrow Hanley Mewhinney & Strauss LLC](https://longbridge.com/en/news/296750367.md)
- [10:03 ET"Fundamentals of Radiation Oncology, 4th Edition" Selected for 2026 Doody's Core Titles in Radiation Oncology](https://longbridge.com/en/news/296503669.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [Monte Rosa doses first patient in Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in mCRPC](https://longbridge.com/en/news/296776784.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**